Fundraising FoxForbion — 2024 Investments
10 investments dated 2024 · listed companies and verified rows first · show all
Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.
BiotechHealthtechMedical DevicesOss, NL
Renato Chirivi(Co-founder (former CSO))in
BoardPaul Peter Tak(Chair of the Board)
Co-investorsBioGeneration VenturesPureos BioventuresSeventure PartnersJohnson & Johnson Innovation – JJDCBOMCurie Capital+1 more
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalLongwood FundNorwest Venture PartnersPivotal Life SciencesRiverVest Venture PartnersYsios Capital+4 more
Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.
BiotechDigital HealthHealthtechMedical Devices
Moin Saleem(Co-founder & Chief Scientific Advisor)in
Co-investorsSofinnova PartnersGilde HealthcareAdvent Life SciencesBritish Patient Capital
Completed patient enrollment in its Phase 2 AURORA trial.
Co-investorsP53 InvestSarsia Management ASInvestinor
LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.
BiotechDeep TechCambridge, GB
David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in
Co-investorsDementia Discovery FundNovartis Venture FundSV Health Investors
NovaMeat develops plant-based protein food products, positioning them as part of a new culinary tradition.
FoodTech
Giuseppe Scionti(Founder)in
Co-investorsAurum Venture PartnersCarbonJoyance PartnersSofinnova PartnersUnovis Asset ManagementVU Venture Partners+1 more
Orbis Medicines is a drug discovery company developing orally bioavailable macrocycle drug candidates as alternatives to injectable biologics, targeting both intracellular and extracellular protein targets.
AI & Machine LearningBiotechDeep Tech
Co-investorsNew Enterprise Associates (NEA)Lilly VenturesNovo Holdings
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)inChristopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)in
BoardAleks Radovic-Moreno(Director)inDan Janney(Director)
Co-investorsAlta PartnersDolby Family VenturesLongwood FundMission BiocapitalService Provider Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Navigator MedicinesBeacon Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.